Using yeast strains with null mutations in structural genes which encode 8-aminolevulinic acid synthetase (HEM)), isozymes of 3-hydroxy-3-methylglutaryl coenzyme A (HMGI and HMG2), squalene epoxidase (ERG)), and fatty acid A9-desaturase (OLEI), we were able to determine the effect of hemes, sterols, and unsaturated fatty acids on both sterol production and the specific activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) in Saccharomyces cerevisiae. We found that the HMGR isozymes direct essentially equal amounts of carbon to the biosynthesis of sterols under heme-competent conditions, despite a huge disparity (57-fold) in the specific activities of the reductases. Our results demonstrate that palmitoleic acid (16:1) acts as a rate-limiting positive regulator and that ergosterol acts as a potent inhibitor of sterol production in strains which possess only the HMGR1 isozyme (HMG1 hmg2). In strains which contain only the HMGR2 isozyme (hmgl HMG2), sterol production was inhibited by oleic acid (18:1) and to a lesser degree by ergosterol. The specific activities of the two reductases (HMGR1 and HMGR2) were found to be differentially regulated by hemes but not by ergosterol, palmitoleic acid, or oleic acid. The disparate effects of unsaturated fatty acids and sterols on these strains lead us to consider the possibility of separate, compartmentalized isoprenoid pathways in S. cerevisiae.
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The branched isoprenoid pathway ( Fig. 1 ) provides a diverse class of biomolecules which serve key roles in protein synthesis (6), protein glycosylation (7), electron transport (12) , cell cycle control (16), and the maintenance of membrane fluidity (4, 9) . Consequently, drugs which inhibit various portions of this pathway have been effective in lowering serum cholesterol levels in humans (1), inhibiting fungal growth (10) , and preventing Ras-mediated oncogenesis (16). A comprehensive understanding of isoprenoid biosynthesis is fundamental to the future exploitation of this pathway.
The yeast Saccharomyces cerevisiae has provided a valuable model system for examining the biosynthesis and function of sterols and other isoprenoids. The conversion of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) to mevalonic acid, a reaction catalyzed by HMG CoA reductase (HMGR), has long been considered to be the principal regulatory reaction in the synthesis of isopentenoids (15, 18) . We previously showed that heme competency in the S. cerevisiae sterol auxotroph FY3 elicited a fivefold increase in HMGR activity which resulted in a marked accumulation of sterol precursors (8) . Two structural genes (HMG1 and HMG2) which encode isozymes of HMGR have been identified (3) . The expression of HMG1 is positively regulated in the presence of heme by an interaction with the HAPI (CYPI) transcriptional regulator, whereas heme competency represses HMG2 expression by an unknown mechanism (23 were harvested as described below, washed twice with distilled water, and resuspended in water to an optical density at 600 nm (OD6w) of approximately 1.00. Three samples of 10 ml each were then taken to be analyzed for acetate incorporation as follows. Cells were pelleted, resuspended in 0.1 N HCl, steamed for 30 min, and saponified in methanolic KOH (5) . Nonsaponifiable lipids were extracted twice with hexane and once with hexane-diethyl ether (2:1, vol/vol). The extracts were combined and evaporated to dryness, and lipids were separated by thin-layer chromatography as described by Skipski et al. (20) . The thin-layer chromatography plates were scanned for radioactivity by using a Bioscan 200 imaging system. Radioactive bands corresponding to squalene, lanosterol, and 14-demethyl sterols (ergosterol) were scraped into a 20-ml scintillation vial, and 10 ml of Aquasol LS cocktail (Amersham) was added.
Radioactivity was determined by using a Beckman LS 5801 liquid scintillation system. The counts (disintegrations per minute) from these mevalonate-derived nonsaponifiable lipids (MNLs) were added together to determine total MNL radioactivity. MNL production is given as (total dpm in MNL/ml of sample)/OD6w of sample. All experiments were performed a minimum of three times; each sample within the experiment was analyzed in triplicate. The standard deviation for each triplicate was no larger than 10% for any sample. The mean values for repetitive experiments agreed within 25%.
HMGR assay. HMGR was assayed essentially as described by Thorness et al. (23) , with the following modifications. The assay mixture contained 50 mM Tris hydrochloride (pH 7.5), 5 mM dithiothreitol, 3 mM NADPH (type I), 300 ,uM DL-[14C]HMG-CoA (1 ,uCi/,mol), 20 mM glucose-6-phosphate, and 0.1 U of glucose-6-phosphate dehydrogenase. The reaction mixture was incubated for 8 min at 37°C after the addition of 200 ,ug of protein from the cell extract. 'Each sample was assayed a minimum of four times before the mean HMGR activity was determined. The standard deviation was not larger than 20% for any sample.
1-Galactosidase assay. Cultures were grown as described above, and ,3-galactosidase activity was assayed as described by Miller (11) . All experiments were performed in triplicate. The standard deviation was not larger than 10% for any given experiment.
RESULTS
HMGR activity and MNL production vary over the culture cycle. JRY2111 (heml HMGJ hmg2) and JRY2101 (heml hmgl HMG2) were grown on ALA at 100 and 0.5 ,ug/ml, respectively, to allow for optimal expression of each isozyme (23) . Maximal stimulation of HMGR1 (JRY2111) specific activity was observed during logarithmic growth, while HMGR2 (JRY2101) specific activity was optimal during stationary phase (Fig. 2) . MNL accumulation over the culture cycle corresponded to reductase activity in both JRY2111 and JRY2101 (Fig. 2) . On the basis of these data, we chose to harvest cells after 30 h when examining HMG1 and after 50 h when examining HMG2. (Fig. 3) . Palmitic, oleic, and stearic acids elicited no such response. Palmitoleic acid stimulates MNL production but not HMGR1 specific activity. Production of palmitoleic acid is contingent on the heme (cytochrome b5)-requiring OLEI gene product, fatty acid A -desaturase (22) . Consequently, palmitoleic acid is produced by the addition of ALA to heml mutants. We therefore sought to determine whether the previously reported effects of ALA (23) [1-14CJacetate (0.1 p,Ci/ml) was added to one half for quantitation of MNLs; the sister culture was used to determine the specific activity of HMGR1. As shown in These experiments demonstrate that palmitoleic acid does not increase MNL production by increasing the expression of HMG1 or the specific activity of HMGR1. Furthermore, palmitoleic acid is shown to facilitate the conversion of mevalonate to MNL at wild-type (ALA-supplemented) levels, even though HMGR1 activity (and presumably mevalonate production) is fully repressed. This finding suggests that less than 2% (compare specific activities in Table 2 ) of the mevalonate produced under heme-competent conditions is actually needed for sterol biosynthesis.
Ergosterol inhibits HMGR1-mediated MNL production. Another consequence of heme competency in yeast cells, in addition to the initiation of UFA biosynthesis, is the biosynthesis of the major sterol end product, ergosterol. We therefore sought to determine whether sterol production would feedback inhibit HMGR1-mediated MNL production. Strain KC112B (heml ergl HMGI hmg2) was a segregant from a cross between FY14 (heml ergl) and JRY2111 (heml (Table 3) .
Oleic acid and ALA inhibit HMGR2-mediated MNL production. The ability of heme to inhibit the expression of HMG2 has previously been reported (23) . We sought to determine whether UFAs were involved in the regulation of HMG2 expression or HMGR2-mediated MNL production. JRY2101 (heml hmgl HMG2) was grown on defined medium, harvested, and reinoculated to unsupplemented medium or medium containing ALA, palmitoleic acid, or oleic acid. After 50 h of growth, both ALA and oleic acid supplementation caused a fivefold decrease in HMGR2-mediated MNL production ( Table 2 , experiment B). The addition of ALA inhibited the specific activity of HMGR2, whereas oleic acid had no effect on reductase activity.
The level of HMG2 expression was virtually unaltered in KC11-Z2 (heml hmgl HMG2 HMG2-lacZ) grown on medium supplemented with oleic acid in comparison with an unsupplemented control culture (72.0 versus 68.1 Miller units, respectively).
When ALA was added to the medium of KC1011 (heml hmgl HMG2 olel), both the specific activity of the reductase and MNL production were significantly decreased ( Table 2 , experiment B), demonstrating that the inhibitory effects of ALA (heme) were separate and independent of those observed with oleic acid.
Ergosterol slightly decreases HMGR2-mediated MNL production. Strain KC111 (heml ergl hmgl HMG2) was used to examine the effects of sterols on MNL production. Cells grown on ergosterol had 33% less radioactivity incorporated into MNLs than did cells grown on lanosterol (Table 3) .
Comparison of MNL production and isozyme activities in JRY2111 and JRY2101. During our study, it became apparent that isozyme activity was not necessarily indicative of MNL production. To investigate this observation further, JRY2111 and JRY2101 were grown in parallel cultures, with and without the addition of ALA (200 p,g/ml). Cells were harvested after 50 h, and isozyme activities and MNL production were determined. The results (Table 4) demonstrate that under conditions of heme competency (ALA supplemented), the in vitro specific activity of HMGR was 57-fold higher in JRY2111 (HMGR1) than in JRY2101 (HMGR2), although levels of MNL production were essentially equal.?Under heme-depleted conditions, the specific activity of the reductase in JRY2101 (HMGR2) was 10- (Fig. 3) . The ability of palmitoleic acid (16:1) to stimulate MNL production in the absence of ALA was structur- ally specific in that oleic (18:1), stearic (18:0), and palmitic (16:0) acids had no effect.
To examine the effects of heme and UFAs independently, we introduced an insertionally inactivated OLEI gene (olel ::LEU2) into a strain containing null mutations in HEMI and HMG2. The resulting strain was incapable of producing UFAs even under heme-competent (ALA-supplemented) conditions. The data in Table 2 demonstrate that heme mediated a 47-fold increase in HMGR1 activity in the absence of UFAs. ALA supplementation alone, however, did not invoke a significant increase in HMGR1-mediated MNL production. Conversely, palmitoleic acid did not elevate HMG1 expression or HMGR1 activity yet elicited a sixfold increase in MNL production. These data indicate that palmitoleic acid biosynthesis, not increased HMGR1 activity, is the primary contributor in the heme-mediated stimulation of MNL production. These results demonstrate that the effects that we have observed are unique and separate from the previously reported effects of heme or heme-derived products on HMG1 (23) .
Both ALA (heme) and oleic acid repressed HMGR2-mediated MNL production in JRY2101 (heml hmgl HMG2) ( Table 2 , experiment B). The addition of ALA significantly reduced the specific activity of HMGR2, while addition of oleic acid did not. ALA supplementation also caused a reduction in both the specific activity of HMGR2 and MNL production in KC1011 (heml olel hmgl), which is unable to synthesize UFAs even during heme-competent growth. These data lead us to conclude that the effects of ALA and oleic acid are independent, such that heme reduces MNL production at the level of HMG2 expression, regardless of UFA availability. Oleic acid represses MNL production by an unknown mechanism which apparently does not involve the repression of HMG2 expression or HMGR2 specific activity. There have been conflicting reports on the ability of ergosterol to feedback inhibit sterol biosynthesis in S. cerevisiae (2, 5, 13, 17, 21) . In light of our new data on the differential effects of heme and UFAs on MNL production, it now appears that the discrepancies probably arose because of the differences in conditions under which the experiments were performed. Our current work demonstrates that ergosterol is an effective inhibitor of HMGR1-mediated sterol biosynthesis and only moderately affects MNL production, when mevalonate is formed by HMGR2 (Table 3) . Although the site of action of ergosterol is not presently known, it does not appear to be at the level of HMGR.
Throughout the course of our investigation, it became apparent that the specific activity of the reductase was not necessarily indicative of total MNL production. Therefore, reductase specific activities and levels of MNL production in JRY2111 and JRY2101 were compared ( Table 4 ). The most striking results were observed when we compared the two strains under conditions of heme competency (ALA supplemented). Although the specific activity of the reductase was 57-fold higher in JRY2111 than in JRY2101 (the difference is even greater if total activity over the culture cycle is taken into account), equal amounts of radiolabeled acetate were found in the MNLs. We speculate that this finding could be a reflection of partitioning in the HMGJ pathway, which may be directing the carbon flow to other isopentenoids. These data also corroborate our assertion that only a relatively small percentage of the mevalonate produced by HMGR is needed to satisfy fully the sterol requirements of the cells.
If the mevalonate which originates from the HMG isozymes were part of a common (single) isopentenoid biosynthetic pathway, then one might expect equal subsequent metabolism of mevalonate to MNLs. This is clearly not the case. When mevalonate is formed via HMGR1, its metabolism to MNLs is limited by palmitoleic acid availability, unaffected by oleic acid, and strongly inhibited by ergosterol. Conversely, HMGR2-mediated MNL production is unaffected by palmitoleic acid, inhibited by oleic acid, and only moderately decreased in the presence of ergosterol. In light of the fact that the regulatory interactions that we have observed are independent of the expression of the HMG genes or activity of the reductase isozymes but are directly related to the source of mevalonate, we anticipate that the pathways headed by these two isozymes are not only separate but also physiologically compartmentalized such that they are unable to share enzymes. Just as the research described here would not have been possible without the genetic separation of the two HMGR isozymes, future work on the pathways may be inconclusive until mutants that allow the further genetic separation of the pathways are identified. Research toward that end is in progress in our laboratory.
